NCT05163886View on ClinicalTrials.gov

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

January 11, 2023

Study Completion Date

May 31, 2025

Conditions
Amyotrophic Lateral SclerosisALS
Interventions
DRUG

LAM-002A

LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.

OTHER

Placebo

Microcrystalline cellulose in Swedish orange, size 0 capsules.

Trial Locations (3)

21205

Johns Hopkins University School of Medicine, Baltimore

52242

University of Iowa Hospitals and Clinics, Iowa City

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

OrphAI Therapeutics

INDUSTRY

NCT05163886 - Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter